Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goldhirsch

Showing results (501-510 of 753) with videos related to

Pageof 76
Sort By:
Cancer|December 22, 2005
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trialsLorenzo Gianni, Ilaria Panzini, Sigui Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptorsM Colleoni, I Minchella, G Mazzarol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2001
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxelD Crivellari, O Pagani, A Veronesi, et al.
Breast Cancer Research and Treatment|April 3, 2012
Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancerElisabetta Munzone, E Botteri, A Sciandivasci, et al.
Breast Care (Basel, Switzerland)|January 15, 2020
European Guidelines on the Organisation of Breast Centres and Voluntary Certification ProcessesLaura Biganzoli, Lorenza Marotti, Maria-Joao Cardoso, et al.
Clinical Breast Cancer|October 6, 2010
Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancerElisabetta Munzone, Franco Nolé, Aron Goldhirsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancerGiuseppe Curigliano, Giuseppe Viale, Vincenzo Bagnardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2009
A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancerM Colleoni, V Bagnardi, N Rotmensz, et al.
Breast (Edinburgh, Scotland)|July 4, 2008
Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptorsRosalba Torrisi, Silvia Dellapasqua, Raffaella Ghisini, et al.
Anti-Cancer Drugs|November 1, 2006
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancerAndrea Rocca, Giulia Peruzzotti, Raffaella Ghisini, et al.
Pageof 76

Showing results (501-510 of 753) with videos related to

Sort By:
Pageof 76
Cancer|December 22, 2005
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trialsLorenzo Gianni, Ilaria Panzini, Sigui Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptorsM Colleoni, I Minchella, G Mazzarol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2001
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxelD Crivellari, O Pagani, A Veronesi, et al.
Breast Cancer Research and Treatment|April 3, 2012
Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancerElisabetta Munzone, E Botteri, A Sciandivasci, et al.
Breast Care (Basel, Switzerland)|January 15, 2020
European Guidelines on the Organisation of Breast Centres and Voluntary Certification ProcessesLaura Biganzoli, Lorenza Marotti, Maria-Joao Cardoso, et al.
Clinical Breast Cancer|October 6, 2010
Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancerElisabetta Munzone, Franco Nolé, Aron Goldhirsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancerGiuseppe Curigliano, Giuseppe Viale, Vincenzo Bagnardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2009
A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancerM Colleoni, V Bagnardi, N Rotmensz, et al.
Breast (Edinburgh, Scotland)|July 4, 2008
Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptorsRosalba Torrisi, Silvia Dellapasqua, Raffaella Ghisini, et al.
Anti-Cancer Drugs|November 1, 2006
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancerAndrea Rocca, Giulia Peruzzotti, Raffaella Ghisini, et al.
Pageof 76